Choosing a BTK Inhibitor vs Time-Limited Treatment for CLL: Kerry Rogers, MD

For patients with chronic lymphocytic leukemia (CLL), the expanding treatment landscape has made frontline treatment decisions more complex: whether to use continuous Bruton tyrosine kinase (BTK) inhibition or a fixed-duration venetoclax-based regimen. Kerry Rogers, MD, associate professor at The James/The Ohio State University Comprehensive Cancer Center, explained that the choice is not only about pharmacology; it also depends on disease biology, lifestyle, and patient preferences.

In her practice, 2 major drivers shape the frontline treatment decision. The first is molecular. Patients with TP53 mutations or deletion 17p (del[17p]) in their CLL occupy a unique position in the treatment landscape. With virtually every therapy except BTK inhibitors, this genetic profile shortens progression-free survival. Continuous BTK inhibition is one of the only strategies that brings these high-risk patients close to statistical parity with those who don’t carry those alterations. Rogers noted that this remarkable clinical fact shapes frontline recommendations in a significant way.

The second driver is something that doesn’t always make it into trial end points: what the patient actually wants from their daily life. Some are working full-time and can’t step away for a venetoclax ramp-up, while others are retired and prioritizing travel, golf, or simply not spending extra hours in a clinic. The simplicity of a daily oral BTK inhibitor—“Take the pill, go about your business,” Rogers said—is, for many patients, not a trivial consideration; it’s the whole point.

There’s also a third scenario that rarely surfaces in trial populations: patients who are significantly unwell from conditions beyond their CLL, where the goal is simply to minimize their symptom burden without layering on the complexity of combination therapy. For those patients, BTK monotherapy quietly fills a gap that the clinical data haven’t fully captured.

In part 2 of her recent interview with The American Journal of Managed Care^®, Rogers delved into all of it: the evidence, the nuance, and the patient conversations that don’t fit neatly into treatment guidelines.